Ask about this productRelated genes to: PDE9A antibody
- Gene:
- PDE9A NIH gene
- Name:
- phosphodiesterase 9A
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 21q22.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-06-12
- Date modifiied:
- 2014-11-19
Related products to: PDE9A antibody
Related articles to: PDE9A antibody
- New therapeutic strategies for heart failure are urgently needed. The protective effects of cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) pathway on heart have been widely reported. Despite phosphodiesterase 9A (PDE9A) inhibitors combating cardiac remodeling, clinically available drugs are lacking. Hederagenin (HED) is a natural bioactive compound that possesses a wide range of pharmacological activities. However, the role of HED in cardiac remodeling and its underlying mechanisms remains elusive. This study aimed to investigate the effects of HED on cardiac remodeling and its molecular targets. - Source: PubMed
Publication date: 2026/02/26
Chen LiqianZhou XinghongYou YantingChen JieyuPeng BaizhaoDeng YijianJi ShuaiYang YingChen XiaohuLiu HuaxiYang ShuxuanKwan Hiu YeeJin WenZhang LeiWang YuegangZhao XiaoshanLiu Yanyan - Dysregulation in the production of cyclic nucleotides and the upregulation of cyclic nucleotide phosphodiesterases (PDEs) are implicated in many tumor pathologies. Therefore, a comprehensive investigation of PDEs and their dysfunction across different cancers is necessary. In this study, we conducted an in-depth analysis of the genomic expression and variation profiles of PDEs across multiple cancer types. We found that PDE6C, PDE6D, PDE6H, and PDE7A were significantly upregulated in nearly all types of cancer, whereas PDE2A was downregulated in 15 cancer types. Our results demonstrated that somatic copy number alterations (SCNAs) and promoter DNA methylation in pan-cancer samples were heterogeneous and may regulate the expression of PDEs in tumors. We further observed that the expression of PDEs predominantly influences the prognosis of solid tumors. Five differentially expressed PDEs (PDE5A, PDE6D, PDE8A, PDE8B, and PDE9A) were identified as independent prognostic factors for patients with pan-cancer in both the training and testing cohorts. To our knowledge, this is the first study to construct a PDE signature in pan-cancer and to highlight the pivotal role of PDE4D in LIHC (liver hepatocellular carcinoma). - Source: PubMed
Publication date: 2025/12/12
Wu ZenghongRen HuiliGuo Feng - Hit-to-lead (H2L) optimization is a critical stage in small-molecule drug discovery, where efficient exploration of chemical space is required to identify promising lead compounds. Conventional H2L workflows rely on iterative synthesis and experimental evaluation, which limit the range of chemical space that can be explored. In contrast, in silico approaches enable efficient selection of promising compounds from a much larger chemical space by generating large numbers of virtual compounds and evaluating them computationally. To harness this potential, we developed an in silico-driven H2L protocol that integrates molecular generation, binding affinity prediction based on relative binding free energies calculated using the non-equilibrium switching (NES) method, and the evaluation of key properties-such as solubility, metabolic stability, and membrane permeability-using machine learning (ML) techniques. In this study, within the context of H2L optimization, we examined the applicability, accuracy, and utility of NES, a relatively new high-precision binding free energy calculation method, and evaluated its effectiveness in large-scale exploration of substituent space. The phosphodiesterase 9A inhibitor was used as a model system. Starting from the reported high-throughput screening hit compound, we first modified the core structure and then sequentially conducted large-scale exploration of two substitution sites. Following this protocol, we narrowed down compounds predicted to those exhibiting not only high binding affinity but also favorable physicochemical and ADME-related properties. Among these, we verified whether the lead compound reported in the literature was included, and confirmed that it appeared as one of the top-ranked candidates. These results demonstrate that an in silico protocol combining large-scale molecular generation, high-accuracy affinity prediction using NES, and ML-based ADME prediction enables H2L optimization that considers a broader substituent space. - Source: PubMed
Publication date: 2025/12/19
Ogawa HiroyukiOhta MasateruIkeguchi Mitsunori - The beneficial effects of natriuretic peptide receptor activation are mediated by cyclic guanosine monophosphate (cGMP). Phosphodiesterase 9 (PDE9) hydrolyzes cGMP and therefore its inhibition has the potential to increase intracellular cGMP signaling. - Source: PubMed
Publication date: 2025/10/31
Udelson James EBělohlávek JanDukát AndrejEzekowitz JustinGoland SorelMerkely BelaO'Meara EileenPetrie Mark CPonikowski PiotrSenni MicheleTokmakova MariyaVardeny OrlyClaggett BrianMoore ElizabethSavard MeghanMcKellar HillarySurks Howard KSolomon Scott DMcMurray John J V - The tumor microenvironment (TME) in gastric cancer (GC) exhibits immunosuppressive features that facilitate tumor advancement and obstruct the effectiveness of immunotherapy. The role of tripartite motif 32 (TRIM32) in the TME has not been extensively studied. - Source: PubMed
Publication date: 2025/10/29
Wang ChangmingZhu XujunWang JunHu ZhiqingXiang PengchengXu JianXu JiapengCai Qingping